Vir Biotechnology Inc. (VIR), which had a lackluster reception to its initial public offering, has gained 35 percent over the last 5 trading days but is still trading below its offering price of $20 per share.
Shares of Viela Bio Inc. (VIE), which have been hitting new highs, are up a whopping 100% since the Company's market debut on October 3, 2019.
Shares of Lannett Company Inc. (LCI) have gained more than 20 percent over the last five trading days.
Shares of Momenta Pharmaceuticals Inc. (MNTA) are up nearly 63 percent over the last one month as the Company approaches key data readouts across its clinical programs.
I-Mab is a clinical stage biopharmaceutical company developing novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders.
Shares of biopharmaceutical company Atreca Inc. (BCEL) have gained 13 percent over the last one month as the Company advances its drug candidate into clinical testing.
Shares of Fulcrum Therapeutics Inc. (FULC) have gained 65 percent over the last one month as the Company progresses with its lead drug candidate Losmapimod in facioscapulohumeral dystrophy.
Shares of Applied Genetic Technologies Corp. (AGTC) have returned nearly 49 percent over the last one month as the Company gears up to report additional results from X-linked retinitis pigmentosa (XLRP) and achromatopsia trial results this month.
The American depositary shares of BioNTech SE (BNTX), which made market debut as recently as October 10, 2019, are up an impressive 170 percent based on yesterday's closing price of $44.58.
As we ready to step into 2020, it's time to take a look at some of the healthcare IPOs that failed to impress investors in 2019. As of now, 76 healthcare companies have made their debut on the bourses in 2019 versus more than 80 in the previous year and 50 in 2017.
Shares of Quest Diagnostics Incorporated (DGX), which touched a 52-week high of $108.95 in intraday trading yesterday, are up nearly 35 percent year-to-date.
Shares of Amneal Pharmaceuticals Inc. (AMRX) have nearly doubled over the last 28 trading days and trade around $5.40.
Shares of Stryker Corp. (SYK), a medical technology company, are up in pre-market trading today.
2019 saw more than 25 acquisition deals being executed in the biotech sector, of which 14 were billion-dollar deals. Bristol-Myers Squibb (BMY) acquiring Celgene for $74 billion in January remains the most expensive acquisition of this year.
Shares of MEDNAX Inc. (MD) have climbed over 5% in the last 4 trading days.